ROCHE's RESEARCH CHIEF IS RONALD KUNTZMAN, PhD
ROCHE's RESEARCH CHIEF IS RONALD KUNTZMAN, PhD, who took over the top scientist job on Oct. 15 upon the retirement of John Burns, PhD. Kuntzman, 51, began with Roche in 1970 as associate director of biochemistry and drug metabolism, and has held a series of top research positions with the company. In 1979 he became director of pharmaceutical research and development and in 1981 he was named a VP. Kuntzman also becomes a member of Roche's exec cmte. and board of directors. A Brooklyn College graduate, Kuntzman took his MS and PhD degrees from George Washington University. He has authored or co-authored nearly 200 research articles and abstracts, and is a member of the American Society of Pharmacology and Experimental Therapeutics, serving as secty.-treasurer of that group from 1981-1984. In a press release announcing the transition, Roche highlighted the similarities in the backgrounds of Kuntzman and his predecessor Burns, who has headed Roche R&D since 1966. Both are New York natives, Roche said, and both men's research careers have included stops at the Natl. Institutes of Health and at the Wellcome Research Laboratories. Kuntzman will be supervising a Roche research program which is emphasizing biotechnology and vitamin research, which was Burns' specialty. The firm is currently conducting clinical trials with leukocyte A and leukocyte D biosynthetic interferon, and Roche is also working with interleukin-2 for use in immune deficiency conditions. Other products in clinicals include: aniracetam, a mental performance enhancing product; Tegison (etretinate), an antipsoriatic; and nitrazepam, an anticonvulsant/hypnotic. The firm is also continuing to work with Zantac (ranitidine) for additional ulcer uses.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth